Gyrase inhibitors and uses thereof

Abstract

The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.

1 . A compound of formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         W is selected from nitrogen, CH, or CF; 
         X is selected from CH or CF; 
         Z is O or NH; 
         R 1  is phenyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein:
 R 1  is substituted with 0-3 groups independently selected from -(T) y -Ar, R′, oxo, C(O)R′, CO 2 R′, OR′, N(R′) 2 , SR′, NO 2 , halogen, CN, C(O)N(R′) 2 , NR′C(O)R′, SO 2 R′, SO 2 N(R) 2 , or NR′SO 2 R′; 
 
         y is 0 or 1; 
         T is a straight or branched C 1-4  alkylidene chain, wherein one methylene unit of T is optionally replaced by —O—, —NH—, or —S—; 
         each R′ is independently selected from hydrogen, C 1-4  aliphatic, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
 R′ is substituted with 0-3 groups independently selected from halogen, oxo, R o , N(R o ) 2 , OR o , CO 2 R o , NR o C(O)R o , C(O)N(R o ) 2 , SO 2 R o , SO 2 N(R o ) 2 , or NR o , SO 2 R o , wherein: 
 each R o  is independently selected from hydrogen, C 1-4  aliphatic, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein: 
 two substituents on adjacent positions of R 1  may be taken together to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 
 
         Ar is a 3-8 membered saturated, unsaturated, or aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
 Ar is substituted with 0-3 groups independently selected from R′, oxo, CO 2 R′, OR′, N(R′) 2 , SR′, NO 2 , halogen, CN, C(O)N(R′) 2 , NR′C(O)R′, SO 2 R′, C(O)R′, SO 2 N(R′) 2 , or NR′SO 2 R′; 
 
         R 2  is selected from hydrogen or a C 1-3  aliphatic group; and 
         Ring A is a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, provided that said ring has a hydrogen-bond acceptor in the position adjacent to the point of attachment to Ring B, wherein:
 Ring A is substituted with 0-3 groups independently selected from R′, oxo, CO 2 R′, OR′, N(R′) 2 , SR′, NO 2 , halogen, CN, C(O)N(R′) 2 , NR′C(O)R′, SO 2 R′, SO 2 N(R′) 2 , or NR′SO 2 R′, and wherein: 
 two substituents on adjacent positions of Ring A may be taken together to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 
 
       
     
     
         2 . The compound according to  claim 1 , wherein Ring A is selected from the following optionally substituted rings: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         3 . The compound according to  claim 2 , wherein Ring A is an optionally substituted ring selected from rings a, f, l, s, w, y, or z: 
       
         
           
           
               
               
           
         
       
     
     
         4 . The compound according to  claim 1 , wherein:
 R 1  is selected from an optionally substituted phenyl or 5-6 membered heteroaryl ring having 1-2 nitrogens.   
     
     
         5 . The compound according to  claim 4 , wherein R 1  is an optionally substituted ring selected from pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, or imidazol-5-yl. 
     
     
         6 . The compound according to  claim 5 , wherein R 1  is substituted with 0-2 groups independently selected from halogen, oxo, R′, CO 2 R′, OR′, N(R′) 2 , SR′, C(O)N(R) 2 , NR′C(O)R′, SO 2 R′, SO 2 N(R′) 2 , or NR′SO 2 R′. 
     
     
         7 . The compound according to  claim 6 , wherein R 2  is selected from methyl, ethyl, isopropyl, or cyclopropyl. 
     
     
         8 - 16 . (canceled) 
     
     
         17 . The compound according to  claim 1 , wherein said compound is of formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         18 . (canceled) 
     
     
         19 . The compound according to  claim 1  wherein R 2  is ethyl. 
     
     
         20 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         and I-295. 
       
     
     
         21 . A composition comprising a compound according to  claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
     
     
         22 - 24 . (canceled) 
     
     
         25 . A method of inhibiting gyrase and TopoIV activity in a patient, comprising the step of contacting said patient with a composition according to  claim 21 . 
     
     
         26 . A method of decreasing bacterial quantity in a patient, comprising the step of administering to said patient a composition according to  claim 21 . 
     
     
         27 . A method of treating, preventing, or lessening the severity of, a bacterial infection in a patient, comprising the step of administering to said patient a composition according to  claim 21 . 
     
     
         28 . The method according to  claim 27 , wherein the bacterial infection to be treated is characterized by the presence of one or more of the following:  Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter  sps.  Proteus  sps.  Pseudomonas aeruginosa, E. coli, Serratia marcesens, Staphylococcus aureus, Coag. Neg. Staph, Haemophilus influenzae, Bacillus anthracis, Mycoplasma pneumoniae, Moraxella catarralis, Chlamydia pneumoniae, Legionella pneumophila, Staphylococcus epidermidis, Mycobacterium tuberculosis , or  Helcoibacter pylori.    
     
     
         29 . The method according to  claim 28 , wherein the bacterial infection to be treated is selected from one or more of the following: a urinary tract infection, a respiratory infection, pneumonia, prostatitis, a skin or soft tissue infection, an intra-abdominal infection, a blood stream infection, or an infection of febrile neutropenic patients. 
     
     
         30 . The method according to  claim 29 , further comprising the step of administering to said patient an additional therapeutic agent either as part of a multiple dosage form together with said compound or as a separate dosage form. 
     
     
         31 . (canceled)